Abstract 4841
Background
Recent population studies have shown an increase in cancer rates in patients after burn injury over a 30-year follow-up period. This work aims to understand the mediators and mechanisms that lead to cancer susceptibility after acute burn.
Methods
In silico analytics with Watson for Drug Discovery were performed to interrogate networks and pathways in common between burn injury and cancer to better understand the possible mechanistic links. We then useda murine non-severe burn injury model (injury to ∼ 6% body surface area) with subsequent tumor susceptibility evaluation using B16 melanoma challenge 4 weeks after the burn injury. Primary tumor growth (n = 10) and metastasis (n = 11-13) were assessed compared to sham controls.
Results
Network analysis highlighted multiple overlapping pathways important in burn repair and in tumors. In particular, the evidence suggested links to pathways important in the immune response to burn injury (including well characterized pro-inflammatory genes such as IL-6 and TNF-α) and matrix remodeling (such as MMP9) to metastasis. In the murine model, at four weeks after burn injury, primary tumor growth was unaffected (mean volume 353.7mm3± 235.4 vs 256.8mm3± 122.6, burn injury and control respectively, p = 0.32). However, mean number of metastases in burn injury mice was significantly increased (7.7± 4.1 compared with 2.6 ± 1.8 for control mice (p = 0.0015)), and there was a trend for increased metastatic tumor volume (mean volume 2.7 ± 1.2 compared with 1.6 ±1.3 cm3 respectively, p = 0.08) after burn injury.
Conclusions
This work suggests burn injury increases cancer susceptibility, specifically through increased number and size of metastases. Further work to delineate the mechanism, potentially through modulation of in silico-identified immune system and metastasis pathways, may provide potential to improve long-term health outcomes for patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fiona Woods Institute.
Funding
IBM Watson Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract